Kirsty

Insulin aspart, the active ingredient in Kirsty, is an insulin analog presented as a clear solution for subcutaneous use. It is used to improve blood glucose control in patients with Type 1 and Type 2 diabetes mellitus.

GNH USA supplies Kirsty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin aspart in Kirsty is a rapid‑acting insulin analog used in the management of diabetes mellitus.

Type 1 diabetes mellitus: provides mealtime insulin to lower post‑prandial glucose levels. Type 2 diabetes mellitus: used as part of intensive insulin regimens to achieve target glycaemic control. Postprandial hyperglycemia: reduces post‑meal glucose excursions when administered before meals.

Insulin aspart may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose levels that may cause sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycemia: prolonged low blood glucose leading to seizures or loss of consciousness. - Hypokalemia: low serum potassium levels that may affect cardiac function. - Acute insulin allergy: systemic allergic manifestations such as rash, urticaria, or angioedema.

When using insulin aspart, several precautions should be observed to ensure safe and effective therapy.

- Dose adjustment: tailor insulin dose based on blood glucose monitoring, diet, and activity level. - Renal impairment: monitor closely as reduced clearance may increase risk of hypoglycemia. - Pregnancy: use only if benefits outweigh risks; consult healthcare provider for individualized assessment. - Concomitant medications: review other drugs that affect glucose levels, such as sulfonylureas or beta‑blockers. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin aspart can interact with other medicines, altering its glucose‑lowering effect or increasing adverse risk.

Major Interactions (Avoid): - Sulfonylureas: combined use may cause severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - Corticosteroids: can reduce insulin effectiveness, requiring dose increase.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may potentiate hypoglycemic effect. - Diuretics (thiazides): can affect potassium levels and glucose control. - Oral contraceptives: may slightly increase insulin requirements.